Stockscreener 앱 받기
1.555
3.67%
0.055
전일 마감가:
$1.50
열려 있는:
$1.51
하루 거래량:
109.10K
Relative Volume:
0.31
시가총액:
$66.70M
수익:
$51.13M
순이익/손실:
$-93.80M
주가수익비율:
-0.6973
EPS:
-2.23
순현금흐름:
$-129.10M
1주 성능:
+8.74%
1개월 성능:
+10.28%
6개월 성능:
+28.51%
1년 성능:
-60.03%
1일 변동 폭
$1.5005
$1.5622
1주일 범위
$1.50
$1.68
52주 변동 폭
$0.89
$4.22
Repare Therapeutics Inc Stock (RPTX) Company Profile
명칭
Repare Therapeutics Inc
전화
(857) 412-7018
주소
7171 FREDERICK BANTING, SAINT-LAURENT, QC
RPTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.555 | 67.34M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.25 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.64 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.17 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.20 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.89 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-06-09 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | 개시 | CapitalOne | Overweight |
| 2022-04-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-17 | 재개 | Goldman | Buy |
| 2021-09-23 | 개시 | Stifel | Buy |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2021-06-28 | 개시 | Guggenheim | Buy |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2020-10-28 | 개시 | Northland Capital | Outperform |
| 2020-07-14 | 개시 | Cowen | Outperform |
| 2020-07-14 | 개시 | Goldman | Neutral |
| 2020-07-14 | 개시 | Morgan Stanley | Overweight |
| 2020-07-14 | 개시 | Piper Sandler | Overweight |
모두보기
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
What analysts say about Repare Therapeutics Inc. stockRecord-breaking gains - jammulinksnews.com
What drives Repare Therapeutics Inc. stock priceFree AI-Backed Trading Signals - jammulinksnews.com
Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com
Is Repare Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance
How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus
Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits
how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa
What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria
Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Forums - Newser
Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus
Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria
Repare Therapeutics jumps on cancer drug licensing deal - TradingView
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - Business Wire
Repare Therapeutics (NASDAQ:RPTX) Trading Down 4.9%What's Next? - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4.9% – Should You Sell? - Defense World
Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal - Insider Monkey
Is Repare Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Repare Therapeutics Holds Annual Shareholder Meeting - TipRanks
Millennium Management LLC Acquires 67,638 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Shares Down 1.3%Here's Why - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% – What’s Next? - Defense World
Companion Diagnostic Markets Report 2025-2029: Diagnostic Firms Jockey for Position as Pharmaceutical Partnerships Flourish, Discover the Impact of AI - GlobeNewswire Inc.
Repare Therapeutics Inc (RPTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Repare Therapeutics Inc 주식 (RPTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 12 '25 |
Sale |
1.14 |
5,611 |
6,397 |
80,297 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 12 '25 |
Sale |
1.14 |
6,884 |
7,848 |
54,786 |
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Mar 12 '25 |
Sale |
1.14 |
21,179 |
24,144 |
124,394 |
0.65%
자본화:
|
볼륨(24시간):